Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy

Table 4

Stopping rules for PI-based therapy.

Timepoint	Criteria for stopping	Action
Telaprevir (TVR) [5]
Week 4 or 12	HCV-RNA > 1000 IU/mL	Discontinue; TVR/PEG-IFN/RBV
Week 24	HCV-RNA detectable	Discontinue; PEG-IFN/RBV
Boceprevir (BOC) [6]
Week 12	HCV-RNA ≥ 100 IU/mL	Discontinue; BOC/PEG-IFN/RBV
Week 24	Confirmed, detectable HCV-RNA	Discontinue; BOC/PEG-IFN/RBV